Table 1.

Demographic and clinical characteristics of participants with psychoses (PSY) and healthy controls (HC)

	Men				Women
Characteristic	Healthy control men (HC-M) (n=22)		PSY men (PSY-M) (n=16)		Healthy control women (HC-W) (n=17)		PSY women (PSY-W) (n=16)
	Mean	SD	Mean	SD	Mean	SD	Mean	SD
Age (years)	45.32	3.00	43.06	5.37	45.00†	2.06	40.69	6.26
Parental SESa	6.62	1.51	5.36	1.83	4.85	1.24	6.45	1.59
Education (years)	14.45	2.65	13.33	3.09	13.91	1.73	13.78	2.15
Estimated Full Scale IQb	107.86	16.69	103.38	20.25	99.47	14.40	91.79	14.58
Age at symptom onset (years)	--	--	18.07	2.84	--	--	22.6	5.27
Duration of illness (years)	--	--	20.43	5.89	--	--	15.52	7.34
Ethnicity (%Caucasian)c	21/22	95%	15/16	94%	17/17	100%	6/16	38%
Current psychotropic medicationd	--	--	13/16	81%	--	--	9/16	56%
Type of psychosise	--	--	7 AP	9 NP	--	--	10 AP	6 NP

^†Significant mean difference in female participants: HC>PSY, t(31)=2.69, p<0.01.

^aParental socioeconomic status (SES) was a composite index of family income, education, and occupation and ranged from 0.0 (low) to 9.5 (high).

^bFull Scale IQ estimated using the sum of age-scaled scores from the WAIS-R Vocabulary and Block Design subtests, and Sattler’s conversion table C-37 (Sattler, 1992) (p. 851). Data available on only 15 of 16 male PSY subjects and 15 of 16 female HC subjects.

^cOne HC male and one PSY male were African American; Five PSY females were African American and two PSY females were Asian American.

^dThirteen PSY men and nine PSY women were currently taking antipsychotic medications including aripiprazole, clozapine, olanzapine, paliperidone, perphenazine, quetiapine, risperidone, thiothixene, trifluoperazine and valproic acid.

^eAP = affective psychosis; NP = non-affective psychosis.